Does prednisone and fludrocortisone (Florinef) increase the risk of spreading ovarian tuberculosis (TB)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Prednisone and fludrocortisone may increase the risk of spreading ovarian tuberculosis due to their immunosuppressive effects, and their use should be carefully considered in patients with known or suspected ovarian TB, as stated in the most recent guidelines 1. The medications in question, prednisone and fludrocortisone, are corticosteroids that can suppress the immune system, which is the body's natural defense against infections, including tuberculosis (TB) 1. When the immune system is weakened by these medications, existing TB infections can worsen or spread more easily throughout the body. For patients with known or suspected ovarian tuberculosis, these medications should generally be avoided unless absolutely necessary for another condition, and then only under close medical supervision 1. If a patient has ovarian TB and requires corticosteroid treatment for another condition, their doctor should monitor them closely and may prescribe anti-TB medications simultaneously to prevent the spread of the infection. The immunosuppressive effects of prednisone are typically stronger than those of fludrocortisone, which primarily affects salt and water balance, but both medications can potentially compromise immune function and allow TB to spread more readily in the body. According to the European Association of Urology guidelines on urological infections, genitourinary TB, which includes ovarian TB, is often underestimated, and its diagnosis relies on a high index of suspicion, along with microbiological, molecular, and histological testing, as well as imaging findings 1. The guidelines recommend combination drug therapy as the first-line treatment for genitourinary TB, and patients with ovarian TB should be managed accordingly to prevent the spread of the infection. In general, the use of corticosteroids like prednisone and fludrocortisone in patients with TB should be approached with caution, as they can increase the risk of reactivation of TB, especially in patients with compromised immune systems 1. Therefore, the use of prednisone and fludrocortisone in patients with ovarian TB should be carefully weighed against the potential risks, and alternative treatments should be considered whenever possible, as recommended by the most recent and highest quality study 1. Some key points to consider include:

  • The immunosuppressive effects of prednisone and fludrocortisone can increase the risk of spreading ovarian TB.
  • Patients with known or suspected ovarian TB should be closely monitored if they require corticosteroid treatment.
  • Anti-TB medications may be prescribed simultaneously with corticosteroids to prevent the spread of the infection.
  • The diagnosis of genitourinary TB, including ovarian TB, relies on a high index of suspicion and combination of diagnostic tests.
  • Combination drug therapy is the first-line treatment for genitourinary TB, as recommended by the European Association of Urology guidelines 1.

From the FDA Drug Label

Corticosteroids, including prednisone tablets, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens Corticosteroids can: • Reduce resistance to new infections • Exacerbate existing infections • Increase the risk of disseminated infections • Increase the risk of reactivation or exacerbation of latent infections • Mask some signs of infection If prednisone tablets is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur.

The use of prednisone and fludrocortisone may increase the risk of spreading ovarian tuberculosis (TB) due to the immunosuppressive effects of corticosteroids, which can:

  • Exacerbate existing infections
  • Increase the risk of disseminated infections
  • Increase the risk of reactivation or exacerbation of latent infections 2

From the Research

Effect of Prednisone and Fludrocortisone on Ovarian TB

  • There is no direct evidence to suggest that prednisone and fludrocortisone increase the risk of spreading ovarian tuberculosis (TB) 3, 4, 5, 6, 7.
  • However, it is known that corticosteroids, such as prednisone, can suppress the immune system, which may potentially worsen TB infections 4, 6.
  • A study on the use of prednisolone in the treatment of HIV-positive tuberculosis patients found that prednisolone was beneficial in reducing symptoms, but it also increased the risk of certain side effects, such as herpes zoster and Kaposi's sarcoma 6.
  • Another study found that prophylactic prednisone can safely reduce the incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS) in patients at high risk for the syndrome 7.
  • It is essential to note that the use of corticosteroids, such as prednisone and fludrocortisone, should be carefully considered and monitored in patients with TB, especially those with ovarian TB, to minimize potential risks and maximize benefits.

Key Considerations

  • The decision to use prednisone and fludrocortisone in patients with ovarian TB should be made on a case-by-case basis, taking into account the individual patient's condition, medical history, and potential risks and benefits 4, 5, 6, 7.
  • Patients on prednisone and fludrocortisone should be closely monitored for signs of TB progression or worsening of symptoms, as well as potential side effects of corticosteroid therapy 4, 6.
  • Further research is needed to fully understand the effects of prednisone and fludrocortisone on ovarian TB and to determine the optimal treatment strategies for patients with this condition.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Multi drug resistant female genital tuberculosis: A preliminary report.

European journal of obstetrics, gynecology, and reproductive biology, 2017

Research

Corticosteroids and tuberculosis: risks and use as adjunct therapy.

Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1993

Research

Corticosteroids in primary tuberculosis with bronchial obstruction.

Archives of disease in childhood, 1990

Related Questions

Is a 5-day trial of prednisolone (corticosteroid) 20 mg appropriate for a 46 kg patient with tuberculosis (TB) pleurisy, experiencing continuous chest pain that worsens with breathing, and unable to take deep breaths, currently in the continuation phase of treatment with 4 months completed?
When are steroids, such as prednisolone (corticosteroid), indicated for patients with tuberculosis (TB)?
Can levofloxacin and ethambutol be used together in the continuation phase of tuberculosis (TB) treatment?
Can prednisone (corticosteroid) 10mg/tab twice daily (BID) be given to a patient currently undergoing non-pulmonary tuberculosis treatment?
Can a trial of prednisolone (corticosteroid) 20 mg be done in a 46 kg patient with tuberculosis (TB) pleurisy, currently in the continuation phase, without cough or fever, and will it improve appetite?
What is the comparison between ATACH II (Antihypertensive Treatment of Acute Cerebral Hemorrhage II) and INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial) studies in terms of blood pressure targets for patients with intracerebral hemorrhage?
What is the prognosis of placental abruption?
What is the evidence for the use of steroids in patients with brain tumors and when is it contraindicated?
What is the recommended azithromycin (Zithromax) dosing for Community-Acquired Pneumonia (CAP) in a patient with impaired renal function, specifically a creatinine level of 2.7 and a Glomerular Filtration Rate (GFR) of 23?
What are the most common symptoms of marginal cord insertion?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.